Copyright
©2012 Baishideng. All rights reserved.
World J Transplant. Jun 24, 2012; 2(3): 35-40
Published online Jun 24, 2012. doi: 10.5500/wjt.v2.i3.35
Published online Jun 24, 2012. doi: 10.5500/wjt.v2.i3.35
Ischaemic/reperfusion injury: Role of infliximab
Atul Bagul, Transplant Division, III Department, University of Leicester, Leicester-UK and University Hospitals of Leicester, Leicester LE5 4PW, United Kingdom
Author contributions: Bagul A solely contributed to this paper.
Correspondence to: Atul Bagul, MBBS, MRCS, MD, FRCS, NIHR Lecturer, Transplant Division, III Department, University of Leicester, Leicester-UK and University Hospitals of Leicester, Leicester LE5 4PW, United Kingdom. atulbagul@yahoo.com
Telephone: +44-11-62584601 Fax: +44-11-62490064
Received: June 24, 2011
Revised: April 12, 2012
Accepted: June 1, 2012
Published online: June 24, 2012
Revised: April 12, 2012
Accepted: June 1, 2012
Published online: June 24, 2012
Abstract
Ischaemia/reperfusion (I/R) injury is an underlying complex interrelated patho-physiological process which effects the outcome of many clinical situations, in particular transplantation. Tumor necrosis factor (TNF)-α is a pleiotropic inflammatory cytokine; a trimeric protein encoded within the major histocompatibility complex which plays a pivotal role in this disease process. This review is based at looking into an update, particularly the new insights in the mechanisms of action of TNF antagonist such as infliximab. Infliximab may thus play a dual role in the field of transplantation where it might not only down regulate the I/R injury, it may also have a beneficial role in the reduction of acute rejection.